Neuraltus achieves last patient out for NP001, NP002 studies

Oct 5 2010

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies:  a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).  NP001 is a novel small molecule that regulates macrophage activation, with potential application to a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.  NP002 is a small molecule, nicotinic receptor agonist.  All patients enrolled in both studies have completed protocol procedures, and reporting of top-line results is expected by November.

Andrew Gengos, Neuraltus' President and CEO, will present an update on Neuraltus' clinical pipeline at the 9th Annual BIO Investor Forum at the Palace Hotel in San Francisco on Tuesday, October 5, 2010.  Mr. Gengos' presentation will begin at 3:00 pm PT (6:00 pm ET) and will be available upon request through Neuraltus' website at www.neuraltus.com.

Mr. Gengos commented, "We are pleased with the efficiency and speed of our clinical programs, which represent new, first-in-class approaches to treating each target disease indication.  This applies as well to our third program nearing the clinic, NP003, which has potential application in treating lysosomal storage disorders such as Fabry's disease and Gaucher's disease, as well as Parkinson's disease."

SOURCE Neuraltus Pharmaceuticals